Rekvina Labs Ltd
₹ 4.50
0.00%
13 Dec 2021
About
Rekvina Laboratories is engaged in manufacturing injections, liquids, ointments, tablets and capsules.
[
edit about
]
[
add key points
]
- Market Cap ₹ 2.71 Cr.
- Current Price ₹ 4.50
- High / Low ₹ /
- Stock P/E
- Book Value ₹ -0.28
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 5.00
Pros
Cons
- Company has low interest coverage ratio.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.08 | 0.08 | 0.03 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | -0.04 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 0.06 | 0.05 | 0.03 | 0.12 | 0.05 | 0.10 | 0.15 | 0.06 | 0.04 | 0.00 | 0.02 | 0.14 | 0.17 | |
| Operating Profit | 0.02 | 0.03 | 0.00 | -0.06 | -0.05 | -0.10 | -0.15 | -0.06 | -0.08 | 0.00 | -0.02 | -0.14 | -0.17 |
| OPM % | 25.00% | 37.50% | 0.00% | -100.00% | |||||||||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.02 | 0.15 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.02 | 0.03 | 0.00 | -0.06 | -0.02 | -0.08 | 0.00 | -0.06 | -0.08 | 0.00 | -0.02 | -0.14 | -0.17 |
| Tax % | 0.00% | 33.33% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| 0.02 | 0.02 | 0.00 | -0.06 | -0.02 | -0.08 | 0.00 | -0.06 | -0.08 | 0.00 | -0.02 | -0.14 | -0.17 | |
| EPS in Rs | 0.02 | 0.02 | 0.00 | -0.05 | -0.02 | -0.07 | 0.00 | -0.05 | -0.07 | 0.00 | -0.02 | -0.12 | -0.14 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -37% |
| TTM: | -1600% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -6% |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 |
| Reserves | -2.36 | -2.33 | -2.45 | -2.51 | -2.53 | -2.61 | -2.86 | -2.92 | -3.00 | -3.00 | -3.02 | -3.35 |
| 0.00 | 0.00 | 0.01 | 0.01 | 0.17 | 0.21 | 0.00 | 0.00 | 0.00 | 0.08 | 0.09 | 0.25 | |
| 0.08 | 0.09 | 0.09 | 0.13 | 0.14 | 0.19 | 0.13 | 0.15 | 0.18 | 0.11 | 0.13 | 0.12 | |
| Total Liabilities | 0.73 | 0.77 | 0.66 | 0.64 | 0.79 | 0.80 | 0.28 | 0.24 | 0.19 | 0.20 | 0.21 | 0.03 |
| 0.27 | 0.27 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.00 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.00 |
| 0.41 | 0.45 | 0.46 | 0.44 | 0.59 | 0.60 | 0.08 | 0.04 | -0.01 | 0.00 | 0.01 | 0.03 | |
| Total Assets | 0.73 | 0.77 | 0.66 | 0.64 | 0.79 | 0.80 | 0.28 | 0.24 | 0.19 | 0.20 | 0.21 | 0.03 |
Cash Flows
Figures in Rs. Crores
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.01 | -0.02 | -0.04 | 0.01 | -0.02 | -0.01 | -0.01 | -0.04 | 0.01 | 0.00 | |||
| 0.01 | 0.02 | 0.07 | -0.07 | 0.00 | 0.00 | 0.00 | 0.04 | 0.00 | 0.00 | |||
| 0.00 | 0.01 | 0.00 | 0.16 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Net Cash Flow | 0.00 | 0.00 | 0.03 | 0.10 | 0.01 | -0.01 | -0.01 | 0.00 | 0.01 | 0.00 |
Ratios
Figures in Rs. Crores
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 730.00 | 1,003.75 | 3,041.67 | 1,703.33 | 0.00 | |||||||
| Inventory Days | 0.00 | |||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 730.00 | 1,003.75 | 3,041.67 | 1,703.33 | 0.00 | |||||||
| Working Capital Days | 1,368.75 | 1,460.00 | 4,015.00 | 1,460.00 | -1,642.50 | |||||||
| ROCE % | 3.10% | 4.51% | 0.00% | -11.11% | -3.45% | -12.70% | -50.00% | -160.00% | 0.00% | -23.53% |
Documents
Announcements
-
Financial Results QTR 1
13 Aug - Rekvina Labs reports Q1 FY26 standalone loss of Rs 3.54 Lacs; limited review completed.
-
Board Meeting Outcome for OUTCOME OF BOARD MEETING
13 Aug - Q1 FY2026 standalone unaudited loss of Rs 3.54 Lacs approved; limited review completed.
-
Board Meeting Intimation for Rescheduled Meeting To Be Held On 13.08.2025.
12 Aug - Board meeting postponed to Aug 13 for Q1 results; trading window closed till Aug 16.
-
Board Meeting Intimation for Meeting To Be Held On 12Th August, 2025.
4 Aug - Board meeting on 12 Aug 2025 to approve Q1 unaudited results; trading window closed from 1 July.
-
Announcement under Regulation 30 (LODR)-Change in Registered Office Address
4 Aug - Clarification: Registered office remains same; new address is corporate office only.